KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Cash & Equivalents (2016 - 2025)

Petmed Express' Cash & Equivalents history spans 16 years, with the latest figure at $26.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 46.28% year-over-year to $26.9 million; the TTM value through Dec 2025 reached $26.9 million, down 46.28%, while the annual FY2025 figure was $54.7 million, 1.05% down from the prior year.
  • Cash & Equivalents reached $26.9 million in Q4 2025 per PETS's latest filing, down from $36.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $118.7 million in Q1 2021 to a low of $26.9 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $74.6 million, with a median of $58.4 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: grew 28.79% in 2021, then crashed 51.77% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $108.9 million in 2021, then dropped by 5.95% to $102.4 million in 2022, then plummeted by 51.77% to $49.4 million in 2023, then grew by 1.42% to $50.1 million in 2024, then tumbled by 46.28% to $26.9 million in 2025.
  • Per Business Quant, the three most recent readings for PETS's Cash & Equivalents are $26.9 million (Q4 2025), $36.1 million (Q3 2025), and $41.1 million (Q2 2025).